Background
PD-1 activation by its ligands (PD-L1 and PD-L2) inhibits T-cell activation and plays a role in cancer progression. PD-L1 is widely expressed in many cell types in tumor microenvironment. In contrast, expression of PD-1 is restricted to a small subset of T-lymphocytes. Inhibition of PD-1/PD-L1 interaction showed no benefit in a small number of colorectal cancers studied in clinical trials. We investigated tumor infiltrating PD-1+lymphosytes and PD-L1 expressing cells in CRC to gain insight in their role as biomarkers.
Download Publication